Filing Details
- Accession Number:
- 0001179110-10-012306
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-08-05 13:00:00
- Reporting Period:
- 2010-08-03
- Filing Date:
- 2010-08-05
- Accepted Time:
- 2010-08-05 17:46:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1294284 | Ganesh Venkataraman | C/O Momenta Pharmaceuticals, Inc. 675 West Kendall Street Cambridge MA 02142 | Senior V.p., Research | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2010-08-03 | 15,116 | $22.07 | 366,874 | No | 4 | S | Direct | |
Common Stock | Disposition | 2010-08-05 | 2,584 | $17.67 | 364,290 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2006.
- This transaction was executed in multiple trades at prices ranging from $21.90 to $22.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $17.60 to $17.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.